Abstract
P2RY13, a purinergic receptor belonging to the P2Y family of G-protein-coupled receptors, has garnered increasing attention for its potential involvement in cancer biology. This review explores the multifaceted role of P2RY13 in cancer development and progression, aiming to provide a comprehensive understanding of its implications for cancer diagnosis, prognosis, and therapy. Utilizing data mining techniques and bioinformatics analysis on publicly available datasets, we investigated the differential expression of P2RY13 across various cancer types and its correlation with clinical features, survival outcomes, tumor immune microenvironment, and molecular characteristics. Our analysis revealed significant dysregulation of P2RY13 expression in tumors, with distinct associations with malignant features and patient prognosis. Notably, P2RY13 expression was found to correlate with immune-related biomarkers and tumor stemness, highlighting its potential role in modulating tumor immunity and heterogeneity. Furthermore, our study identified correlations between P2RY13 expression and immune cell infiltration, immune checkpoint genes, and other immune regulatory genes, underscoring its importance in tumor immune modulation. Despite the insights gained, further mechanistic studies are warranted to elucidate the precise role of P2RY13 in cancer biology and to explore its therapeutic potential as a target for cancer treatment.